Contract analysis

I. Executive Summary This memorandum has been prepared at the request of Penterra Pharmaceuticals Corp. ("Penterra" or "PPC") to analyze whether the compensation structure proposed under the Master Clinical Trial Agreement (the "MCTA") between Penterra and Veridian Health Research Network, Inc. ("Veridian" or "VHRN") for Protocol PPC-4871-III — the CLARION trial (Clinical Assessment of Response with Longitudinal Inve

II. Background A. The CLARION Trial and the MCTA Penterra Pharmaceuticals Corp. is sponsoring a Phase III, randomized, double-blind, placebo-controlled, multi-center clinical trial evaluating penterafenib (PPC-4871), an oral multi-kinase inhibitor, for the treatment of advanced hepatocellular carcinoma ("HCC") in the second-line setting following prior systemic therapy. The compound penterafenib is a next-generation

III. Compensation Structure Under the MCTA The proposed MCTA establishes a multi-component compensation framework consisting of per-patient site fees, start-up fees, annual site maintenance fees, investigator grants for academic publication support, a network coordination and administrative fee payable to Veridian central, technology and EDC integration costs, and a contingency/change order reserve. Each component is

IV. Legal Framework: Anti-Kickback Statute A. Overview of the Anti-Kickback Statute The federal Anti-Kickback Statute, codified at 42 U.S.C. § 1320a-7b(b), is one of the cornerstone statutes governing financial relationships in the healthcare industry. The AKS makes it a criminal offense for any person to knowingly and willfully offer, pay, solicit, or receive any remuneration (including any kickback, bribe, or rebat

1. Personal Services and Management Contracts Safe Harbor (42 C.F.R. § 1001.952(d)) The personal services and management contracts safe harbor is the principal safe harbor applicable to the MCTA and the underlying investigator and site services arrangements. This safe harbor protects payments made under service agreements from AKS liability, provided that all of the following requirements are satisfied: (i) The arran

2. Bona Fide Employment Safe Harbor (42 C.F.R. § 1001.952(i)) The bona fide employment safe harbor protects payments made by an employer to an employee for employment in the furnishing of any item or service for which payment may be made under a federal healthcare program, provided that the employment is for identifiable services, and that the amount paid is consistent with fair market value in arms'-length transacti

V. Legal Framework: Physician Payments Sunshine Act / Open Payments A. Overview of the Sunshine Act The Physician Payments Sunshine Act, enacted as Section 6002 of the Affordable Care Act and codified at 42 U.S.C. § 1320a-7h, requires "applicable manufacturers" of drugs, devices, biologicals, or medical supplies covered or reimbursed under Medicare, Medicaid, or the Children's Health Insurance Program ("CHIP") to rep

VI. 21 CFR Part 54 — Financial Disclosure Considerations While the primary focus of this memorandum is on AKS and Sunshine Act compliance, a brief discussion of financial disclosure requirements under 21 C.F.R. Part 54 is warranted, as these requirements intersect with the FMV analysis and the overall compliance framework for the CLARION trial. FDA regulations at 21 C.F.R. Part 54 require sponsors of covered clinical

VII. Tax-Exempt Status Considerations for Veridian and Member Institutions The proposed MCTA implicates considerations related to the tax-exempt status of Veridian Health Research Network, Inc. and its member institutions, several of which are nonprofit corporations. These considerations, while not the primary focus of this memorandum, are relevant to the overall FMV analysis and warrant brief discussion. Veridian He